57 results about "Traitement adjuvant" patented technology

The invention discloses a system and a method for predicting postoperative recurrence risk after triple negative breast cancer neoadjuvant therapy based on multi-modal time sequence medical image data, and belongs to the field of medical image analysis. The system comprises a data processing module used for constructing a multi-modal data set; the multi-modal feature extraction and screening module is used for extracting deep learning, radiomics and tumor habitat features from the region and carrying out feature screening; the model training module is used for constructing a time sequence model based on a Transform architecture and carrying out training through a multi-task learning strategy integrated with time consistency constraint and gene association auxiliary loss; and the recurrence risk prediction module is used for loading the trained model and outputting a recurrence probability and a risk level. According to the method, the multi-modal time sequence image and gene information are fused, so that the recurrence risk of the triple negative breast cancer patient is dynamically and accurately quantified, and support is provided for clinical individualized treatment decision.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention provides a breast cancer adjuvant therapy pathology complete remission prediction method and electronic device.The breast cancer adjuvant therapy pathology complete remission prediction method comprises the steps that at the first stage, based on multi-time-point and multi-parameter MRI images of a patient before and after adjuvant therapy, the breast cancer adjuvant therapy pathology complete remission prediction result is obtained; training an image feature encoder with a tumor dynamic change identification capability through a dynamic supervision pre-training mode; and a second stage of constructing a multi-modal deep fusion network based on the image feature encoder to integrate the image features, radiomics features and clinical pathological features of the patient, and outputting a prediction result of complete pathology remission, the radiomics features being extracted from the MRI image. And the purposes of high precision and strong generalization capability are achieved.

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.

The invention discloses application of a small molecule compound in preparation of a medicine for treating ovarian cancer, and belongs to the technical field of biological medicine. The small molecule compound comprises a structure as shown in a formula (I) or an isomer, a pharmaceutically acceptable solvate or salt thereof, it is found for the first time that the small molecule compound can effectively reduce protein expression of YBX1, and meanwhile in-vitro verification experiments prove that the small molecule compound has a remarkable inhibition effect on proliferation of ovarian cancer cells. In addition, it is found that the small molecule compound can improve the cytotoxicity of cis-platinum and significantly enhance the anti-tumor effect of cis-platinum. The application of the small molecule compound YB-B1 targeting YBX1 in preparation of the medicine for treating the ovarian cancer is disclosed for the first time, a new method and a new idea are provided for clinical treatment of the ovarian cancer, and the small molecule compound YB-B1 particularly has remarkable significance in auxiliary treatment and prevention and treatment of cis-platinum drug-resistant ovarian cancer.

Indivi dualized neoantigen vaccines, as well as methods for their use in subjects to treat urothelial orbladder cancer are provided. In some embodiments, individualized neoantigen vaccines are used with an immune checkpoint inhibitor and optionally enfortumab vedotin to treat a urothelial or bladder cancer after surgical resection. Prior to surgical resection, in some embodiments, the subject is administered a neoadjuvant therapy comprising an immune checkpoint inhibitor, individualized neoantigen vaccines, and, optionally, enfortumab vedotin.

The invention discloses a targeting peptide for blocking combination of IL-17A and IL-17RA / RC and application thereof, the targeting peptide is selected from AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 or a combination of any one of AZS-1, AZS-2, AZS-3, AZS-4 and AZS-5 and IBP, the amino acid sequence of AZS-1 is as shown in SEQ ID NO: 1, the amino acid sequence of AZS-2 is as shown in SEQ ID NO: 2, the amino acid sequence of AZS-3 is as shown in SEQ ID NO: 3, the amino acid sequence of AZS-4 is as shown in SEQ ID NO: 4, and the amino acid sequence of AZS-5 is as shown in SEQ ID NO: 5. The amino acid sequence of the AZS-5 is as shown in SEQ ID NO: 5, and the amino acid sequence of the IBP is as shown in SEQ ID NO: 6. The targeting peptide provided by the invention has good tolerance, can generate effective interaction with the surface of a target protein, can realize specific binding with IL-17A, has relatively high blocking ability, can effectively improve symptoms of liver and kidney cell injury, cell edema and skin injury caused by psoriasis after being applied to a psoriasis mouse model, and has a good application prospect. The compound has a good application prospect in treatment and / or adjuvant therapy of IL-17A-mediated inflammatory diseases.

The application provides a breast cancer patient lymph node metastasis prediction model without clinical pathological characteristics, comprising the following steps: after three-dimensional reconstruction of two-dimensional lung enhanced CT films, an axillary lymph node atlas is established, all axillary lymph nodes in the atlas are selected as ROI regions, and more than 5 combined image features of each axillary lymph node are selected to distinguish whether breast cancer has axillary lymph node metastasis; and a logistic regression machine learning prediction model is used to construct the breast cancer patient axillary lymph node metastasis prediction model. The model established by the application can non-invasively predict whether breast cancer has axillary lymph node metastasis, the clinical pathological characteristics of the patient are not included in the model, and the image cutting in the model is not based on breast tumors, but based on axillary lymph nodes; the model is used to determine a suitable axillary treatment scheme, thereby avoiding unnecessary axillary surgery and complications, and helping to carry out more accurate surgery and adjuvant therapy mode of breast cancer.

The invention belongs to the technical field of biomedicine, and discloses an antibody for evaluating the curative effect of infantile pneumonia asthma and application of the antibody. The heavy chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 2-4, the light chain CDR sequence of the monoclonal antibody (secreted by the hybridoma cell strain 2B5) is SEQ ID NO: 6-8, the dissociation constant of the monoclonal antibody and an IL-5R antigen reaches 2.435 * 10 <-1 > / L, and the affinity is high. The antibody can accurately evaluate the curative effect of infantile pneumonia and asthma by detecting the lung function, the ratio of eosinophilic granulocytes in bronchoalveolar lavage fluid and lung tissue inflammation, can also significantly improve airway obstruction and inflammation of asthma model mice, has an effect superior to that of dexamethasone, solves the problems that existing curative effect evaluation is lack of specific tools and has large side effects of therapeutic drugs, and has good clinical application prospects. And a new scheme is provided for curative effect evaluation and adjuvant therapy of infantile pneumonia asthma.

According to the technical scheme, the pancreatic cancer prognosis prediction system based on deep learning is characterized by comprising a data input module, a preprocessing module, a feature extraction module, a cross sequence attention fusion module and a multi-task prediction module. The system disclosed by the invention can accurately predict the overall lifetime (OS) and the disease-free lifetime (DFS) of the patient by analyzing the preoperative multi-sequence magnetic resonance imaging (MRI) image of the patient, and carries out risk stratification. More importantly, clinical doctors can be guided to formulate personalized adjuvant therapy schemes for patients with different risk levels, for example, whether the patients can benefit from postoperative adjuvant chemotherapy or immunotherapy or not is judged, and therefore precise medical treatment is achieved, the treatment effect is improved, and invalid treatment is avoided.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The present application belongs to the tumor precision medicine and artificial intelligence medical technology field, and particularly relates to a non-small cell lung cancer neoadjuvant immunotherapy efficacy prediction method based on transfer learning. The method first pretreats the non-small cell lung cancer immunotherapy cohort and the neoadjuvant immunotherapy cohort, selects immunotherapy and neoadjuvant immunotherapy characteristic genes, and based thereon, carries out deep learning training on the immunotherapy cohort to obtain a basic model, finally, the basic model is fine-tuned to the neoadjuvant immunotherapy training data set through transfer learning, and finally used to the neoadjuvant immunotherapy cohort to predict the neoadjuvant immunotherapy effect. The present application improves the stability and generalization ability of the model in the small sample neoadjuvant treatment scene through gene selection and transfer fine-tuning, and can be used for clinical auxiliary decision and population stratification.

The invention discloses a sensitizing drug for resisting breast cancer by radiotherapy and a screening method and application thereof, and belongs to the field of biomedicine.The method comprises the steps that an in-vitro radiotherapy resistance model is constructed, a clinical segmentation radiotherapy dose increasing mode is simulated, stable acquired radiotherapy resistance is induced to be generated, and a carrier is provided for drug screening; natural plant small molecule compounds are used for treatment, and through concentration and time gradient dual control, the reversion ability of the natural plant small molecule compounds to radiotherapy resistance phenotypes is investigated; a multi-dimensional joint detection system is established, multi-level comprehensive evaluation is performed from cell survival and the like, the limitation of a single index is broken through, and the screening accuracy and reliability are improved; dNA damage repair is dynamically monitored through immunofluorescence, comet electrophoresis and the like, and the drug action mechanism is revealed. The medicine screened by the method is suitable for primary and acquired radiotherapy resistance patients, can effectively improve the radiotherapy curative effect, provides a new medicine source and scheme for clinical problems, and opens up the application of the compound in preparation of radiosensitizers or adjuvant therapy medicines.

The application belongs to the field of biological medicine, and discloses application of an RNA helicase DHX33 inhibitor in preparation of a drug for treating or adjuvant treating thyroid cancer. The application establishes an important role of DHX33 protein in development of thyroid cancer, and provides an inhibitor having an action of inhibiting DHX33 helicase activity, thereby causing lipid peroxidation mediated by DHX33 deletion, and inducing interleukin 24 (IL-24) expression in thyroid cancer cells. The inhibitor can rapidly induce cancer cell ferroptosis, and significantly inhibit thyroid cancer cell proliferation through up-regulation of IL-24, and therefore has important medical development value.

The application provides a protein marker for predicting the sensitivity of adjuvant chemotherapy of an ovarian cancer patient and an application, based on proteomics data of an ovarian cancer tissue sample, combining a preliminary screening model and a classification model and PRM technology, screening a plurality of protein markers with representative meanings for predicting the sensitivity of adjuvant chemotherapy of an ovarian cancer patient after neoadjuvant therapy, training an ovarian cancer patient chemotherapy sensitivity prediction model by using the screened protein markers, predicting the chemotherapy sensitivity of an ovarian cancer patient who has not undergone adjuvant therapy by using the ovarian cancer patient chemotherapy sensitivity prediction model, if the chemotherapy sensitivity is low, it means that the probability of recurrence of the patient after 6 months of adjuvant therapy is high, so medical staff can adjust the treatment plan accordingly, avoid unnecessary chemotherapy treatment for ovarian cancer patients, and play a preventive effect.

The present invention relates to anti-GDF15 antibodies for use in neoadjuvant therapy of cancer.

The invention belongs to the technical field of biological medicines, discloses a ganoderma lucidum oligopeptide for inhibiting tumor cell growth and a preparation method and application thereof, and aims to overcome the technical defects of unknown active ingredients, low yield, poor purity and high toxicity of the existing ganoderma lucidum oligopeptide. The sequence of the ganoderma lucidum oligopeptide is Trp-Gly-Ala-Pro-Arg, the molecular weight is 623.7 Da, the isoelectric point is 8.92, and the ganoderma lucidum oligopeptide plays a tumor inhibition role by reducing a PI3K / Akt / mTOR signal channel in a targeted manner. The preparation method comprises the following steps: carrying out superfine grinding on a lucid ganoderma raw material, carrying out composite enzymatic hydrolysis by using papain, alkaline protease and flavourzyme (5: 3: 2), and carrying out ultrafiltration, gel chromatography and RP-HPLC (Reverse Phase-High Performance Liquid Chromatography) purification, so that the yield is 1.16-1.20%, and the purity is greater than or equal to 98%. The ICs of the peptide to six tumor cells such as lung cancer A549 are 0.8-1.4 [mu] mol / L, and the ICs of the peptide to normal cells are ICgt; the therapeutic index is greater than or equal to 15.4; the cells PPappgt of Caco-2 are subjected to cell culture; 1 * 10 cm / s, the plasma protein binding rate is 65%-68%, LDgt; the density is 500 mg / kg. The compound can be prepared into dosage forms such as injections and the like, and the tumor inhibition rate reaches 85% when the compound is combined with cis-platinum, and CI is equal to 0.65. The process is stable, and the product is high in activity, safe, suitable for tumor treatment and adjuvant therapy and good in industrialization prospect.

The invention provides injectable beta-glucan hydrogel with an immunologic adjuvant function as well as a preparation method and application of the beta-glucan hydrogel, and relates to the field of biological medicines. The hydrogel is a macromolecular network which is formed by crosslinking an aldehyde group-containing beta-glucan derivative and an amino-containing polymer through a Schiff base bond and has a remarkable immunologic adjuvant function. The hydrogel and the drug-loading sustained-release system thereof can be directly implanted into a focus position through a conventional medical injector, immune cells are remarkably activated, and the immunogenicity of tumor cells is enhanced, so that the immune microenvironment of solid tumors is effectively adjusted. Particularly, when the beta-glucan derivative hydrogel and the drug sustained-release system thereof provided by the invention are applied in combination with radiotherapy, the beta-glucan derivative hydrogel and the drug sustained-release system thereof show excellent tumor treatment efficiency. The preparation process is simple and mild, the obtained hydrogel has good biocompatibility and controllable drug release characteristics, and a novel and efficient adjuvant therapy strategy is provided for tumor immunotherapy.

The invention discloses an application of a macrocyclic diterpenoid compound component in euphorbia pekinensis fruits in preparation of a tumor chemotherapy drug sensitizer. The macrocyclic diterpenoid compound component in euphorbia pekinensis fruits is combined with paclitaxel to overcome the drug resistance of P-glycoprotein mediated non-small cell lung cancer cells (A549 / Taxol) to paclitaxel; the drug combination improves the sensitivity of A549 / Taxol drug-resistant cells to paclitaxel, enhances the lethality of paclitaxel to lung cancer cells, and promotes apoptosis of lung cancer cells. Reverse drug resistance action mechanism study shows that the macrocyclic diterpenoid compound component in euphorbia pekinensis fruits is used as a P-glycoprotein substrate to activate the activity of ATP enzyme, inhibit the excretion function of P-glycoprotein to paclitaxel and increase the accumulation level of paclitaxel in A549 / Taxol cells so as to play a role in reversing tumor MDR, and then the sensitivity of A549 / Taxol to the chemotherapeutic drug paclitaxel is improved. The sensitization and drug resistance reversal effects and mechanism research can provide a theoretical basis for the adjuvant therapy of lung cancer chemotherapy as a high-efficiency and low-toxicity traditional Chinese medicine reversal agent.

The invention discloses ackermania mucoprotein and application of protein of the ackermania mucoprotein in preparation of drugs for prevention, treatment and adjuvant therapy of colorectal cancer. The ackermania muciniphila belongs to intestinal flora, the abundance of the ackermania muciniphila is in negative correlation with inflammatory bowel disease and inflammatory colorectal cancer, and the abundance of the ackermania muciniphila is in positive correlation with the curative effect of a PD-1 / PD-L1 inhibitor in cancer immunotherapy. Certain domains of Ackermania muciniphila are capable of inhibiting the growth of colorectal cancer tumors.

The invention belongs to the technical field of biology, and particularly relates to an anti-human CD16 monoclonal antibody 12D11 as well as a preparation method and application thereof. The anti-human CD16 monoclonal antibody 12D11 comprises a heavy chain and a light chain, and the amino acid sequence of a heavy chain variable region (mVH) is as shown in SEQ ID NO. 1; the amino acid sequence of the light chain variable region (mVL) is as shown in SEQ ID NO. 2. The anti-human CD16 monoclonal antibody has the beneficial effects that the anti-human CD16 monoclonal antibody is used as a marker on the surface of a natural killer (NK) cell, can be used for immunohistochemical detection of normal tissues and tumor tissues, induces activation and amplification of the NK cell, improves the targeting specificity of the NK cell to a solid tumor, and has a good application prospect. And a more effective adjuvant therapy strategy is expected to be provided for tumor patients.

The invention discloses a liver cancer clinical new auxiliary curative effect prediction system and medium, and the prediction system comprises an input unit which is used for inputting the value of a diagnostic serological detection index of a patient; the prediction unit is used for generating a prediction result of whether the new adjuvant therapy is invalid to the patient or not based on the prediction model and the diagnostic serological detection indexes; and the output unit is used for outputting the prediction result. According to the present invention, the diagnosis serological detection index of the patient can be conveniently and rapidly obtained based on the detection results of the blood biochemical detection, the specific protein detection and the like during the liver cancer treatment process so as to predict whether the new adjuvant therapy of the tiranibizumab combined with the lenvatinib is invalid to the patient based on the diagnosis serological detection index; therefore, the delay of the operation process of a part of patients with invalid new adjuvant therapy is avoided, and the method has wide application value clinically.

The invention discloses an application of a low-intensity magnetic field combined chemotherapy drug in tumor treatment, and belongs to the field of biological medicine, a low-intensity magnetic field environment and a clinically common tumor chemotherapy drug are combined for application, and an in-vitro experiment result shows that the low-intensity magnetic field environment can remarkably improve the treatment effect of the chemotherapy drug. The new application of the weak magnetic field can be used for clinical adjuvant therapy of malignant tumors, the tumor inhibition effect of common chemotherapy drugs is improved, toxic and side effects are reduced, and a new reference basis is provided for clinical prevention and treatment of tumors.

The invention discloses application of AKK bacteria in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis, and belongs to the technical field of microorganisms. In order to solve the technical problems that in the prior art, treatment means for rhinitis cannot relieve symptoms for a long time, the single anti-inflammatory effect is limited, side effects are likely to be caused and the like, the invention provides a new Ackermann mucophila strain AKK IMMU, the AKK IMMU is preserved in Guangdong Microbial Culture Collection Center on November 3, 2025, the preservation number is GDMCC No: 67192, and the AKK IMMU is preserved in the Guangdong Microbial Culture Collection Center on November 2025. The strain can remarkably improve rhinitis model mouse nasal mucosa pathological damage, regulate serum oxidative stress indexes and regulate lung tissue inflammatory factors.

The invention discloses an application of a fresh astragalus source vesicle in preparation of chemotherapy adjuvant drugs. The invention provides and verifies that the fresh astragalus source vesicles have dual effects of enhancing the chemotherapy curative effect and relieving myelosuppression caused by chemotherapy for the first time, and can be used for a novel adjuvant therapy strategy. Meanwhile, the fresh radix astragali source vesicles are derived from medicinal and edible radix astragali, so that the fresh radix astragali source vesicles have the characteristics of high safety and low clinical risk, and a solid foundation is laid for subsequent clinical transformation.

The invention belongs to the technical field of biological medicine, and particularly relates to application of vitamin B12 in preparation of an auxiliary therapeutic agent for preventing or treating colorectal cancer precancerous lesions. The invention aims to solve the technical problem of providing a novel prevention and intervention means for colorectal cancer (CAC) caused by the cancerization process of colorectal adenoma and inflammatory atypical hyperplasia. The invention further provides a preparation method of the novel prevention and intervention means for the colorectal cancer caused by the cancerization process of the colorectal adenoma and the inflammatory atypical hyperplasia of the colorectal adenoma and the colorectal cancer caused by the inflammatory atypical hyperplasia of the colorectal adenoma. In a colorectal adenoma canceration process, the level of vitamin B12 in a circulatory system is reduced along with the development of diseases. In inflammatory and hereditary colorectal cancer mouse models, MHC-II signals can be enhanced by supplementing medicine vitamin B12, and CD4 effect memory T cell immunity can be reactivated. The invention provides a new thought for further researching the immune recovery strategy in the colorectal cancer precancerous lesion process and the medical application of the vitamin B12.

The invention discloses application of albiflorin in preparation of medicines for adjuvant therapy of cancers, and particularly relates to application of albiflorin in treatment of cancer-related fatigue and tumor-related depression. A chemotherapy-induced CRF blood deficiency and liver depression syndrome mouse model is adopted, the treatment effect of albiflorin on CRF and CRD is investigated through the tumor weight, the inhibition rate, behavioral indexes and peripheral hemogram, and the effect is better than that of a radix paeoniae alba water extract.

The application belongs to the field of textiles, and discloses a fabric for adjuvant therapy of breast cancer and a preparation method thereof. The preparation method comprises the following steps: firstly, preparing a fluorouracil FU and collagen tripeptide CTP compound FU-CTP, incorporating the compound into a core layer spinning solution, preparing a core-shell nanofiber membrane through electrospinning, and finally obtaining the fabric for adjuvant therapy of breast cancer. The fabric can release the compound FU-CTP in the form of micelles, CTP can carry FU, promote the transdermal penetration ability of FU, and enrich FU in the local breast to reach a therapeutic concentration, so that most side effects such as gastrointestinal side effects and bone marrow suppression caused by oral and intravenous administration of FU can be reduced.